drugset / Trial / NCT05089409
A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
RandomizedSequentialDouble-blindTreatment
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis.
Timeline
- Start
- 2022-03-04
- Primary completion
- 2023-06-03
- Completion
- 2023-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATB1651 | Unknown | 2 mg/ml | Topical |
| Subject | ATB1651 | Unknown | 5 mg/ml | Topical |
| Subject | ATB1651 | Unknown | 10 mg/ml | Topical |
| Subject | ATB1651 | Unknown | 20 mg/ml | Topical |
| Subject | ATB1651 | Unknown | 30 mg/ml | Topical |